Eight on-site greywater treatment facilities of four different types (A, B, C and D) were investigated. Three were commercially available package plants (A-C) and one was a conventional sand filter (D). The treatment unit of Type A consisted of a geotextile-fitted trickling filter and a sand filter bottom layer, the Type B consisted of packs of fibrous mineral wool filter materials, and the Type C consisted of a fine-meshed plastic filter. The treatment systems were assessed in terms of their removal efficiency for organic matter (e.g. BOD, COD, TOC), nutrients (nitrogen and phosphorus), surfactants, indicator bacteria (E. coli and enterococci) as well as microplastics. Systems A and D effectively reduced organic matter by >96% BOD, >94% COD and >90% TOC. Their effluent BOD was <29 mg/l. The BOD reduction in the treatment facilities of types B and C was in the range of 70-95%. Removal of anionic surfactants was >90% with effluent concentration <1 mg/l in all facilities. In general, the treatment systems were ineffective in removing E. coli and enterococci; the most efficient was the sand filter (type D), achieving 1.4-3.8 log for E. coli and 2.3-3.3 log for enterococci. Due to the high E. coli in the effluents, all the on-site systems were classified as Poor (score: 0-44) according to the water quality index (WQI) assessment. In two of the studied facilities, nine microplastic polymers were targeted (i.e. PVC, PS, PET, PE, PC, NG, PMMA, PP and PA6) and analyzed using the thermal extraction desorption gas chromatography-mass spectrometry (TED-GCMS) technique. PVC, PS, PET and PA6 were commonly detected in the influent and effluent. The effluent quality from type A and D systems was found to comply with the European Commission's guideline for the reuse of reclaimed water except for the indicator bacteria concentration.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jenvman.2024.121859 | DOI Listing |
Nat Commun
January 2025
British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, Canada.
Cheek swabs, heterogeneous samples consisting primarily of buccal epithelial cells, are widely used in pediatric DNA methylation studies and biomarker creation. However, the decrease in buccal proportion with age in adults remains unexamined in childhood. We analyzed cheek swabs from 4626 typically developing children 2-months to 20-years-old.
View Article and Find Full Text PDFClin Chim Acta
January 2025
Background: Citrin deficiency (CD) is an autosomal recessive metabolic disorder affecting the urea cycle and energy production. Diagnosis involves measuring ammonia, amino acid levels (eg: citrulline), with confirmation through solute carrier family 25 member 13 (SLC25A13) gene mutation analysis. Herein, we present a case report of a variant in the SLC25A13 gene that has not been previously reported in the literature.
View Article and Find Full Text PDFInt J Biol Macromol
January 2025
Fundação de Medicina Tropical - Dr Heitor Vieira Dourado, Manaus, AM, Brazil; Universidade Nilton Lins, Manaus, AM, Brazil. Electronic address:
Background: In settings with low pneumococcal conjugate vaccine (PCV) coverage, multi-age cohort mass campaigns could increase population immunity, and fractional dosing could increase affordability. We aimed to evaluate the effect of mass campaigns on nasopharyngeal pneumococcal carriage of Pneumosil (PCV10) in children aged 1-9 years in Niger.
Methods: In this three-arm, open-label, cluster-randomised trial, 63 clusters of one to four villages in Niger were randomly assigned (3:3:1) using block randomisation to receive campaigns consisting of a single full dose of a 10-valent PCV (Pneumosil), a single one-fifth dose of Pneumosil, or no campaign.
Structure
January 2025
Novartis Biomedical Research, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA. Electronic address:
Inflammatory bowel disease (IBD) consists of chronic conditions that severely impact a patient's health and quality of life. Interleukin-10 (IL-10), a potent anti-inflammatory cytokine has strong genetic links to IBD susceptibility and has shown strong efficacy in IBD rodent models, suggesting it has great therapeutic potential. However, when tested in clinical trials for IBD, recombinant human IL-10 (rhIL-10) showed weak and inconsistent efficacy due to its short half-life and pro-inflammatory properties that counteract the anti-inflammatory efficacy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!